Ventura F V, Ruiter J P, Ijlst L, Almeida I T, Wanders R J
Department of Clinical Biochemistry, University Hospital Amsterdam, The Netherlands.
Biochim Biophys Acta. 1995 Aug 15;1272(1):14-20. doi: 10.1016/0925-4439(95)00064-b.
Long-chain fatty acid oxidation deficient patients present early in life with more severe features than patients with a medium-chain fatty acid oxidation deficiency. This may be related to the more toxic effect of long-chain fatty acid derivatives. In this paper we have studied the effect of different acyl-CoA esters, and palmitoyl-CoA in particular, on succinate-driven oxidative phosphorylation, using digitonin permeabilized human fibroblasts. Palmitoyl-CoA was found to inhibit the succinate-driven oxidative phosphorylation in a concentration dependent manner. If the inhibition of the oxidative phosphorylation system is also expressed under in vivo conditions this might explain some of the abnormalities found in patients with defects in long-chain fatty acid beta-oxidation.
与中链脂肪酸氧化缺陷患者相比,长链脂肪酸氧化缺陷患者在生命早期出现的症状更为严重。这可能与长链脂肪酸衍生物的毒性作用更强有关。在本文中,我们使用洋地黄皂苷通透的人成纤维细胞,研究了不同酰基辅酶A酯(特别是棕榈酰辅酶A)对琥珀酸驱动的氧化磷酸化的影响。发现棕榈酰辅酶A以浓度依赖的方式抑制琥珀酸驱动的氧化磷酸化。如果氧化磷酸化系统的抑制在体内条件下也表现出来,这可能解释了长链脂肪酸β氧化缺陷患者中发现的一些异常情况。